Pneumococcal meningitis and etanercept-chance or association?

Journal of Infection

Volumn 51, Issue 2, 2005, Pages

  Killingley, Ben ^a,b   Carpenter, V ^a   Flanagan, K ^a   Pasvol, G ^a  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Etanercept; Pneumococcal meningitis; Rheumatoid arthritis; Streptococcus pneumoniae

Indexed keywords

AMITRIPTYLINE; CALCICHEW D3; CALCIUM; CEFTRIAXONE; CIPROFLOXACIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FOSINOPRIL; GOLD; IBUPROFEN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; OMEPRAZOLE; PENICILLIN G; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ADULT; ALCOHOLISM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MENINGITIS; CASE REPORT; CERVICAL SPINE; CHRONIC DISEASE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DISEASE ASSOCIATION; DROWSINESS; EXTERNAL OTITIS; FEMALE; FEVER; GASTROESOPHAGEAL REFLUX; GLASGOW COMA SCALE; HEMOFILTRATION; HUMAN; HYPERTENSION; IMMUNE RESPONSE; INFECTION RISK; INTENSIVE CARE UNIT; INTUBATION; KNEE ARTHROPLASTY; LOW DRUG DOSE; MORTALITY; OSTEOPENIA; PROTEIN FUNCTION; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; RIGIDITY; STREPTOCOCCUS PNEUMONIAE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; CEFTRIAXONE; CIPROFLOXACIN; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MENINGITIS, PNEUMOCOCCAL; MIDDLE AGED; OTITIS MEDIA; RECEPTORS, TUMOR NECROSIS FACTOR; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 22144444886     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2004.08.015     Document Type: Article

References (11)

1. F. Bazzoni B. Beutler The tumour necrosis factor ligand and receptor families N Engl J Med 334 1996 1717-1725
2. M. Pasparakis L. Alexopoulou V. Episkopou G. Kollias Immune and inflammatory responses in TNFα deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers and in the maturation of the humoral immune response J Exp Med 184 1996 1397-1411
3. E.H.S. Choy G.S. Panayi Cytokine pathways and joint inflammation in rheumatoid arthritis N Engl J Med 344 2001 907-916
4. S.E. Plevy C.J. Landers J. Prehn A role for TNFα and mucosal T helper-1 cytokines in the pathogenesis of Crohns disease J Immunol 159 1997 6276-6282
5. B. Bresnihan G. Cunnane Infection complications associated with the use of biologic agents Rheum Dis Clin N Am 29 2003 185-202
6. Food and drug administration medicinal watch program. http//www.fda.gov/medwatch.
7. J.M. Bathon R.W. Martin R.M. Fleischmann A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 343 2000 1586-1593
8. M.E. Weinblatt J.M. Kremer A.D. Bankurst A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 1999 253-259
9. L.W. Moreland M.H. Schiff S.W. Baumgartner Etanercept therapy in rheumatoid arthritis: A randomised, controlled trial Ann Intern Med 130 1999 478-486
10. T. Van Der Poll C.V. Keogh W.A. Buurman S.F. Lowry Passive immunisation against TNFα impairs host defence during pneumococcal pneumonia in mice Am J Respir Crit Care Med 155 1997 603-608
11. Anonymous Etanercept and sepsis WHO Drug Inf 13 2 1999 92